Dr. Chari on the INSIGHT MM Study on Multiple Myeloma
Ajai Chari, MD, Icahn School of Medicine at Mount Sinai, discusses INSIGHT MM (NCT02761187), the largest global, prospective, non-interventional, observational study on multiple myeloma to date.
Ajai Chari, MD, associate professor of medicine, hematology and medical oncology, Icahn School of Medicine at Mount Sinai, discusses INSIGHT MM (NCT02761187), the largest global, prospective, non-interventional, observational study on multiple myeloma to date.
Currently, there is no uniform standard of care treatment for patients with multiple myeloma, and an analysis of patients enrolled in INSIGHT MM showed more frequent use of triplets in newly diagnosed multiple myeloma and in younger patients than in relapsed/refractory multiple myeloma and in older patients.
According to Chari, these results highlight the differences in treatments available across the global landscape. Chari and colleagues found that there was greater treatment heterogeneity in relapsed/refractory disease than in newly diagnosed disease, for example, and this heterogeneity was particularly apparent with respect to novel treatment options available, and especially in the United States.
